Familial Alzheimer's Disease
GPTKB entity
Statements (49)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:psychologist
|
| gptkbp:bfsLayer |
6
|
| gptkbp:bfsParent |
gptkb:AD_Genetics
|
| gptkbp:age |
typically before age 65
|
| gptkbp:associated_with |
amyloid plaques
tau tangles neurodegeneration early onset dementia |
| gptkbp:caused_by |
genetic mutations
|
| gptkbp:clinical_trial |
gptkb:physicist
new medications preventive strategies |
| gptkbp:current_use |
gptkb:Sporadic_Alzheimer's_Disease
|
| gptkbp:future_plans |
biomarkers
longitudinal studies therapeutic targets |
| gptkbp:historical_context |
first described in the 1990s
linked to specific genetic mutations |
| https://www.w3.org/2000/01/rdf-schema#label |
Familial Alzheimer's Disease
|
| gptkbp:impact |
healthcare systems
caregivers societal resources |
| gptkbp:is_characterized_by |
cognitive decline
memory loss |
| gptkbp:is_popular_in |
less than 5% of Alzheimer's cases
|
| gptkbp:is_recognized_by |
specific populations
families with multiple affected members |
| gptkbp:promoter |
APP
PSE N1 PSE N2 |
| gptkbp:public_awareness |
gptkb:television_channel
advocacy groups increasing due to research |
| gptkbp:research_focus |
genetic factors
treatment options pathophysiology |
| gptkbp:risk_factor |
family history
|
| gptkbp:social_responsibility |
genetic testing
neuroimaging |
| gptkbp:symptoms |
disorientation
behavioral changes language difficulties |
| gptkbp:transmission |
autosomal dominant inheritance
|
| gptkbp:treatment |
medications
supportive care cognitive therapies emotional burden on families high cost of care lack of curative options |